Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Ossenkoppele

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Hemasphere|March 21, 2022
Clinical value of new drugs in acute myeloid leukemiaGert Ossenkoppele
Blood|December 18, 2014
How I treat the older patient with acute myeloid leukemiaGert Ossenkoppele, Bob Löwenberg
Critical Reviews in Oncology/Hematology|May 17, 2019
Challenges in the diagnosis and treatment of secondary acute myeloid leukemiaGert Ossenkoppele, Pau Montesinos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AMLGert Ossenkoppele, Paresh Vyas
Hematology. American Society of Hematology. Education Program|December 4, 2016
MRD in AML: does it already guide therapy decision-making?Gert Ossenkoppele, Gerrit Jan Schuurhuis
Expert Review of Hematology|November 19, 2010
Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?Gerrit Jan Schuurhuis, Gert Ossenkoppele
Blood|March 23, 2013
MRD in AML: time for redefinition of CR?Gert Ossenkoppele, Gerrit Jan Schuurhuis
European Journal of Haematology|November 1, 2015
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012Noortje Thielen, Otto Visser, Gert Ossenkoppele, et al.
Leukemia|March 6, 2020
Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?Adriano Venditti, Robert Peter Gale, Francesco Buccisano, et al.
Haematologica|May 5, 2012
Towards a joint definition of European hematologyGert Ossenkoppele, Gareth Evans-Jones, Ulrich Jaeger, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Hemasphere|March 21, 2022
Clinical value of new drugs in acute myeloid leukemiaGert Ossenkoppele
Blood|December 18, 2014
How I treat the older patient with acute myeloid leukemiaGert Ossenkoppele, Bob Löwenberg
Critical Reviews in Oncology/Hematology|May 17, 2019
Challenges in the diagnosis and treatment of secondary acute myeloid leukemiaGert Ossenkoppele, Pau Montesinos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AMLGert Ossenkoppele, Paresh Vyas
Hematology. American Society of Hematology. Education Program|December 4, 2016
MRD in AML: does it already guide therapy decision-making?Gert Ossenkoppele, Gerrit Jan Schuurhuis
Expert Review of Hematology|November 19, 2010
Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?Gerrit Jan Schuurhuis, Gert Ossenkoppele
Blood|March 23, 2013
MRD in AML: time for redefinition of CR?Gert Ossenkoppele, Gerrit Jan Schuurhuis
European Journal of Haematology|November 1, 2015
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012Noortje Thielen, Otto Visser, Gert Ossenkoppele, et al.
Leukemia|March 6, 2020
Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?Adriano Venditti, Robert Peter Gale, Francesco Buccisano, et al.
Haematologica|May 5, 2012
Towards a joint definition of European hematologyGert Ossenkoppele, Gareth Evans-Jones, Ulrich Jaeger, et al.
Pageof 6